Financial Performance - The company reported a basic earnings per share of 0.3000 yuan for 2024, an increase of 36.36% compared to 0.2200 yuan in 2023 [1] - Operating revenue reached 3.1 billion yuan, reflecting a growth of 27.57% from 2.43 billion yuan in the previous year [1] - Net profit for the year was 0.22 billion yuan, up 29.41% from 0.17 billion yuan in 2023 [1] - The return on equity improved to 5.61%, a significant increase of 31.38% from 4.27% in the prior year [1] Shareholder Structure - The top ten unrestricted shareholders collectively hold 15.1592 million shares, accounting for 44.69% of the circulating shares, with a decrease of 361,000 shares compared to the previous period [1] - Zhao Zhuojun remains the largest shareholder with 7.7947 million shares, representing 22.98% of the total share capital [2] - New entrants to the top ten shareholders include Yang Yanxia and Ye Lirong, holding 492,600 shares (1.45%) and 57,000 shares (0.17%) respectively [2] Dividend Distribution - The company announced a dividend distribution plan of 10 shares for every 3 shares held, along with a cash dividend of 1 yuan (including tax) [3]
欧康医药:2024年报净利润0.22亿 同比增长29.41%